Search
Immuron Ltd
IMRNAdd to Watchlist
1.100USD
+0.010+0.92%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
6.27MMarket Cap
LossP/E TTM
More Details of Immuron Ltd Company
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Immuron Ltd Info
Ticker SymbolIMRN
Company nameImmuron Ltd
IPO dateApr 30, 1999
CEOLydeamore (Steven)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endApr 30
Address62 Lygon Street
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3053
Phone61398245254
Websitehttps://www.immuron.com.au
Ticker SymbolIMRN
IPO dateApr 30, 1999
CEOLydeamore (Steven)
Company Executives of Immuron Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Pollock
Mr. Daniel Pollock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Dr. Jerry Kanellos, Ph.D.
Dr. Jerry Kanellos, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Prof. Ravi Savarirayan
Prof. Ravi Savarirayan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Brennan
Mr. Paul Brennan
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steven Lydeamore
Mr. Steven Lydeamore
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Jeannette (Jeannie) Joughin
Dr. Jeannette (Jeannie) Joughin
Non-Executive Director
Non-Executive Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Pollock
Mr. Daniel Pollock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Dr. Jerry Kanellos, Ph.D.
Dr. Jerry Kanellos, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Prof. Ravi Savarirayan
Prof. Ravi Savarirayan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Brennan
Mr. Paul Brennan
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steven Lydeamore
Mr. Steven Lydeamore
Chief Executive Officer
Chief Executive Officer
--
--
FAQs
Who are the top five shareholders of Immuron Ltd?
The top five shareholders of Immuron Ltd are: Mr. Daniel Pollock
How many institutions hold shares of Immuron Ltd (IMRN)?
As of 2026Q1, 15 institutions hold shares of Immuron Ltd, with a combined market value of approximately 160.30K, accounting for 1.96% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 54807.00.
What is the biggest source of revenue for Immuron Ltd?
In 2026Q1, the Travelan business generated the highest revenue for Immuron Ltd, amounting to 1.74M and accounting for 96.68% of total revenue.